Senate Judiciary Committee Chair Dick Durbin (D-IL) (Patrick Semansky/AP Images)

Sen­ate Ju­di­cia­ry Com­mit­tee sends five phar­ma-re­lat­ed bills to the floor

The Sen­ate Ju­di­cia­ry Com­mit­tee on Thurs­day ad­vanced five bills via voice vote that will pro­hib­it and slow some of the games phar­ma com­pa­nies of­ten play to ex­tend their mo­nop­o­lies be­fore gener­ic com­pe­ti­tion comes to mar­ket.

One of the five bills aims to pre­serve gener­ic drug and biosim­i­lar ac­cess by pro­hibit­ing brand-name drug com­pa­nies from pay­ing gener­ic drug com­pa­nies to de­lay the mar­ket en­try of com­pe­ti­tion. While these so-called “pay-for-de­lay” deals have de­clined in re­cent years, phar­ma com­pa­nies like No­var­tis re­cent­ly paid $245 mil­lion to set­tle al­le­ga­tions of such a deal for its blood pres­sure drug Ex­forge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.